Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
about
Getting the balance right: Established and emerging therapies for major depressive disordersCYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropionAnimal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletionsThe treatment of depressive disorders in epilepsy: what all neurologists should knowEffects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteersExtended-release bupropion: an antidepressant with a broad spectrum of therapeutic activity?Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects.Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation.Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Bupropion for the treatment of seasonal affective disorder.Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1.Bupropion: pharmacology and therapeutic applications.The use of bupropion SR in cigarette smoking cessationA primary care focus on the treatment of patients with major depressive disorder.Resolution of enantiomers of bupropion and its metabolites by liquid chromatography.Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.Effect of renal impairment on the pharmacokinetics of bupropion and its metabolitesInfluence of acute bupropion pre-treatment on the effects of intranasal cocaineRapid clinical induction of bupropion hydroxylation by metamizole in healthy Chinese men.Bupropion for weight reduction.Overview of the pharmacogenomics of cigarette smoking.Multiple sclerosis symptom management.Cytochromes P450: a structure-based summary of biotransformations using representative substrates.Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state.Bupropion extended-release for depressive disorders.Antenatal Escitalopram Use and Necrotizing Enterocolitis in a Newborn: A Case Report.Bupropion therapy during pregnancy: the drug and its major metabolites in umbilical cord plasma and amniotic fluid.Clinically significant drug interactions with newer antidepressants.Pharmacokinetic drug interactions involving Ginkgo biloba.Carbonyl reduction pathways in drug metabolism.ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram.Association between CYP2D6 Genotypes and the Risk of Antidepressant Discontinuation, Dosage Modification and the Occurrence of Maternal Depression during Pregnancy.Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.The Impact of Psychoactive Drugs on Seizures and Antiepileptic Drugs.Enhancement of nootropic effect of duloxetine and bupropion by caffeine in mice.Single-dose pharmacokinetics of bupropion hydrobromide and metabolites in healthy adolescent and adult subjects.Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis.Stereoselective metabolism of bupropion by cytochrome P4502B6 (CYP2B6) and human liver microsomes.
P2860
Q24610225-0A93AC96-A0B7-401B-B9F4-75D69EDE4108Q24634660-0DC2F698-7D67-40E3-8409-637A200D2093Q24651067-CBD38988-0C8D-4005-9A91-D725817A95BFQ26851858-A13A7384-F9D6-4A88-AC21-1FCF6284EF0CQ28750369-6D8ACEF8-F37A-48CA-902F-FD3EF76404A4Q30442979-F3C0A82E-ECD4-4803-B61C-B0619A6FACC6Q33803436-17E891A8-6904-40C5-93B6-8312E8699487Q33927695-5C1BAC24-60FB-4D7E-9650-09B5053E60B2Q33955964-D8CB66EA-AEA8-454C-9FC0-081875113CA7Q34116690-1B4F25FA-E4B6-427D-91BF-13618C2D17CDQ34346558-C51D2DB0-A3C3-4854-B91B-FB988B26BE35Q34353804-5274B2AC-0B90-4EFC-81EE-151B8879D140Q34569990-7267FBF4-A778-4963-97BB-6BC8177713B7Q34779470-8E1D8353-F7D4-4B2B-A7FE-612DFDB1B2E3Q35207313-7C4FC252-7A81-42E7-9CCA-E022A5FFDFCFQ35731310-C997F45A-5872-438D-86C3-8D3CECC0E651Q35953819-C5E6C5FC-2F0B-4383-A53B-86E5F88FF04FQ36024598-DCA94222-78E8-4FF3-9C6D-99973ED10EE6Q36076392-330CD380-758A-415C-89D3-E64DD75A6DF4Q36468142-1868A853-6CBB-4FC4-BEBA-AB69E12CD277Q36691753-B9FE2DF5-7CA7-4E24-A7ED-C23FF9C17D47Q36708951-B4281A0A-DAD5-41A6-AFED-68AAA76EAFA9Q36941918-702C23AB-FF4D-4FAE-82FF-F8132AEEFE22Q37079954-8BE45E5B-E1F5-40EB-82D0-4EEF3E4F8F10Q37148882-B0D96FD4-7804-43AF-B156-19AAEDF186C4Q37154793-286EBF76-2A64-4B7B-A997-F6E95CAFA9CBQ37527164-EB965050-FFA2-4B4D-94F6-E7E34BC187F2Q37659046-6B25FC01-5AD7-4215-BD28-87BBA28E72DAQ37968621-D2EAF6D9-BFAE-495E-8673-5706C005E5AFQ38122439-0977D3AE-176E-42FE-A702-73494F09DFAFQ38156452-E1FC406C-BC54-4BFE-A031-21E06A2D5DF3Q38242390-22224F4F-58A6-4DBF-9D23-5632E8D8083AQ38592699-DC9B4FDD-EF03-4E76-9478-2B1CE4AAB4FAQ38645670-87A12CC5-3FF2-4A3B-A595-E64C6E143AE8Q38815352-3307C8A6-CFEA-4FDD-999F-5564685B6C0FQ38868459-D5E45EE0-8A91-473D-A72B-C41A7CD76A56Q39257915-7DB3B80A-2796-4575-8550-954ED880FA30Q39802397-F4291B58-1FF7-4305-8087-630F695995E5Q40587312-C4F084D1-8B5A-4660-A3F6-5FDD5E7B00C2Q41153557-3AE9C6B2-19A4-4A96-BE3B-C3A001437AE7
P2860
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@ast
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@en
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@nl
type
label
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@ast
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@en
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@nl
prefLabel
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@ast
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@en
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@nl
P2093
P1476
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
@en
P2093
James F Pradko
James W Jefferson
Keith T Muir
P304
P356
10.1016/J.CLINTHERA.2005.11.011
P577
2005-11-01T00:00:00Z